title: Characterization of humoral and cellular immunity to rubella vaccine in four distinct cohorts.
abstract: Although vaccination campaigns have significantly reduced the global burden of rubella disease, there are still regional outbreaks and cases of congenital rubella syndrome. Rubella vaccination elicits a strong humoral as well as cellular response. The relationship between these two measures in response to rubella vaccine is poorly understood. We have previously reported no correlation between rubella-virus-specific cytokine secretion and IgG antibody levels after rubella vaccination. In the current study, we extend our previous work to report correlations between secreted cytokines and functional neutralizing antibodies after rubella vaccination in four distinct cohorts. There was evidence of significant differences (p < 0.05) in rubella-virus-specific humoral and cellular responses between cohorts. When investigating relationships between rubella-vaccine-specific humoral and cellular immunity, we observed a significant correlation between neutralizing antibodies and IFN-γ (r(s) = 0.21, p = 0.0004). We also observed correlations in subjects with extreme humoral immune phenotypes and IFN-γ levels in two of the four cohorts (r(s) = 0.32, p = 0.01; r(s) = 0.36, p = 0.01, respectively). These findings indicate that there is a high level of heterogeneity in rubella-specific immune responses between study populations. We believe that the novel correlation discovered between IFN-γ and neutralizing antibody titers will give future insight into the functional mechanisms of immunity induced by rubella virus and other live viral vaccines.
authors.affiliation: Mayo Vaccine Research Group, Mayo Clinic, Guggenheim 611C, 200 First Street SW, Rochester, MN, 55905, USA.
authors.forename: Nathaniel D
authors.initials: ND
authors.lastname: Lambert
authors.forename: Iana H
authors.initials: IH
authors.lastname: Haralambieva
authors.forename: Inna G
authors.initials: IG
authors.lastname: Ovsyannikova
authors.forename: Beth R
authors.initials: BR
authors.lastname: Larrabee
authors.forename: V Shane
authors.initials: VS
authors.lastname: Pankratz
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Poland
mesh_terms: D000293:Adolescent; D000328:Adult; D057134:Antibodies, Neutralizing / Q000097:blood / Q000276:immunology; D002140:California; D002648:Child; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D056724:Immunity, Humoral; D007371:Interferon-gamma / Q000097:blood / Q000276:immunology; D015850:Interleukin-6 / Q000097:blood / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008297:Male; D008910:Minnesota; D012409:Rubella / Q000276:immunology* / Q000517:prevention & control*; D012411:Rubella Vaccine / Q000008:administration & dosage* / Q000276:immunology; D012412:Rubella virus / Q000276:immunology*; D018709:Statistics, Nonparametric; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000276:immunology; D055815:Young Adult
chemical_list: D057134:Antibodies, Neutralizing; D015850:Interleukin-6; D012411:Rubella Vaccine; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma